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ORIGINAL ARTICLE VIROLOGYLarge increase of rotavirus diarrhoea in the hospital setting associated
with emergence of G12 genotype in a highly vaccinated population in
NicaraguaF. Bucardo1, J. Mercado2, Y. Reyes1, F. González1, A. Balmaseda2 and J. Nordgren3
1) Department of Microbiology, University of León (UNAN-León), León, 2) National Center for Diagnostic and Reference, Ministry of Health, Managua,
Nicaragua and 3) Division of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, SwedenAbstractRotaviruses (RVs) are a major cause of severe diarrhoea in young children. Nicaragua introduced routine immunization with the pentavalent
RV vaccine (RV5) in 2006, which greatly reduced the incidence of diarrhoea. A remaining concern has been the possible emergence of new
RV strains to which the vaccination has less effect. In this study, 837 children with diarrhoea in hospital settings were investigated for RV
between May 2011 and July 2013. RVs were subsequently typed by multiplex PCR and/or sequencing. Fecal anti-RV IgA titres for a
subset of RV-infected (n = 137) and noninfected children (n = 52) were determined with an in-house enzyme-linked immunosorbent
assay. The RV detection rate was 8% in 2011, followed by a sharp increase to 29% in 2012 and 19% in 2013. This was associated with
emergence and predominance of genotype G12 RV, from 0% in 2011 to 66% in 2012 and 82% in 2013, infecting children from 1 month
to 10 years of age. Two sequenced G12 strains showed a Wa-like genome with genotype G12-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1,
similar to the globally emerging G12 strains. Fecal anti-RV IgA analysis showed that most G12-infected and noninfected children had been
in contact with either vaccine or wild RV strains, but such antibodies did not prevent symptomatic G12 infection. A marked increase of
RV was evident in the hospital setting associated with a nationwide emergence and predominance of RV G12 genotype in a population
with high RV5 vaccine coverage.
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E-mail: ﬁli_bucardo@hotmail.comIntroductionRotavirus (RV) is an important pathogen of severe diarrhoea in
infants and young children globally [1]. A major reduction of
severe RV diarrhoea has been observed in countries with high
RV vaccine coverage, but several clinical trials have shown the
vaccine efﬁcacy to be lower in countries with high RV mortalityClinical Microbiology and Infection © 2015 European Society of C[2]. In countries where universal RV vaccination has been
established, noroviruses have replaced RVs as the most com-
mon cause of children hospitalization for acute gastroenteritis
[3,4]. In October 2006, the Nicaraguan Expanded Program of
Immunization initiated universal RV vaccination with the
pentavalent RV vaccine (G1/G2/G3/G4/P[8]) from Merck
(RV5). Vaccine coverage rapidly reached over 90% and has been
maintained since [5]. A study in 2007–2008 in Nicaragua
showed that the vaccine had an efﬁcacy against severe diar-
rhoea of only 58% [6]. A remaining concern has been the
possible emergence of new RV strains against which the RV
vaccine may be less effective.
RV infecting human are distributed in 12 different G geno-
types and 15 P genotypes, of which ﬁve genotypeClin Microbiol Infect 2015; 21: 603.e1–603.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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603.e2 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIcombinations—G1P[8], G2P[4], G3P[8], G4P[8] and G9P
[8]—accounted for 88% of all RVs strains circulating globally
during the pre-RV vaccine era, with G1P[8] being the globally
dominant strain and with a higher presence in developed (70%)
compared to developing countries (40%) [7].
Several studies in different continents have reported the
emergence and high detection rates of the previously uncom-
mon G12 strain, mainly in combination with P[8]. Detection
rates in a hospital setting between 2005 and 2013 ranged from
10% to 86% in India, Nepal, Niger, Spain, Argentina and
Rochester, Minnesota, USA [8–14].
In the Americas, the G12 genotype in combination with P[9]
were reported in Argentina (1999), Brazil (2003) and Paraguay
(2006) at low frequencies [15–17]. G12P[6] was reported to
circulate in the United States between 1999 and 2006 and in
Brazil between 2009 and 2010, also at low frequencies [18,19].
In contrast, G12P[8] emerged in Argentina during 2008–2009
at high detection rates (24%), and same genotype was associ-
ated with a gastroenteritis outbreaks in Rochester, Minnesota,
USA [11,12]. The G12 genotype strains is classiﬁed in four
discrete genetic groups designated lineage I to IV (LI to LIV)
[20]. The majority (>90%) of the currently known and world-
wide detected G12P[6] and G12P[8] strains belong to LIII [20].
The current study reports a marked increase of RV in the
hospital setting associated with emergence and persistence of
G12 RV in two consecutive diarrhoea season in Nicaragua in
spite of high vaccine coverage (>90%) and presence of fecal
anti-RV IgA during acute phase.Material and methodsStudy sites
Through a hospital based surveillance, a total of 837 children up
to 10 years of age with diarrhoea from Nicaragua were inves-
tigated for RV infection. Samples were collected between May
2011 and December 2013 at ﬁve hospitals participating in the
National Rotavirus Surveillance Network of the Health Ministry
of Nicaragua, including two pediatric hospital of Managua, the
capital city, ‘Fernando Velez Paiz’ (n = 138) and ‘Manuel de Jesus
Rivera’ (n = 320), and the general hospitals of Masaya ‘Hum-
berto Alvarado’ (n = 75), Carazo ‘Santiago de Jinotepe’
(n = 203) and Matagalpa ‘Cesar Amador Molina’ (n = 101).
Sample collection and RV screening
Liquid stool samples were collected in sterile plastic containers
and transported to the National Center for Diagnostic and
Reference (NCDR). Aliquots of nondiluted samples were pre-
pared and kept at −20°C until RV screening by enzyme-linked
immunosorbent assay (ELISA; Oxoid ProSpecT R240396).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectSensitivity and speciﬁcity of the ELISA used was reported to be
75% and 100%, respectively, when compared with reverse
transcription (RT)-PCR [21]. A form containing general infor-
mation regarding children age, gender and place and date of
sample collection was submitted to the NCDR together with
the sample. RV5 vaccination status and information about liquid
stools during the past 24 hours was limited to a few cases.
Determination of fecal IgA titre
Acute-phase titres of fecal IgA anti-RV were determined by
ELISA using a modiﬁcation of method previously described [22].
In brief, microtitre plates of 96 wells (Greiner Bio-One) were
coated with guinea pig antibody to RV (SBL), diluted 1:500 in
carbonate–bicarbonate buffer (pH 9.6) and incubated overnight
at 4°C. After 2 hours’ blocking with phosphate-buffered saline
(PBS)–bovine serum albumin 3%, RV5 vaccine (Merck) diluted
1:100 was added and incubated at 37°C for 1 hour. A total of
100 μL of serially diluted stool (1:20, 1:40, 1:80 and 1:160) was
added and incubated at 37°C for 1 hour, followed by addition of
peroxidase-conjugated anti-human IgA (P0216; DakoCytoma-
tion) diluted 1:2000, and incubated at 37°C for 1 hour. The re-
action was developed for 10 minutes with tetramethylbenzidine
(Thermo Fisher Scientiﬁc) and stopped with 2M H2SO4. Optical
density (OD) was determined at 450 nm in each well. The
reciprocal of the highest stool dilution with OD 0.100 was
considered sample titre. All experiments included negative
control (neonate stool) and PBS for background monitoring.
RNA extraction and RT
Viral RNA was extracted from 200 μL 1:10 stool suspensions
using High Pure Viral RNA Kit (Roche Diagnostics) following
the manufacturer’s instructions. A total of 50 μL of RNA was
collected and stored at −20°C until RT. RT was carried out as
described previously [23].
G-multiplex genotyping
The G genotypes were determined by PCR using generic and
genotype-speciﬁc primers used for detecting VP7 genotypes G1,
G2, G3, G4, G8, G9, G10 and G12, as described previously
[24,25].
VP7 and VP4 sequencing
A subset of 15 RV-positive samples, representing different G
genotypes and different time and place of collection were
sequenced in the VP7 and VP4 genes. The 881 bp and 876 bp
amplicons obtained from VP7 and VP4, respectively, were
sequenced by Macrogen using VP7-F, VP7-R, Con-3 and Con-2
as sequencing primers [24]. GenBank accession numbers for
VP7 are KM668708 to KM668722 and for VP4, KM668723 to
KM668736.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e1–603.e7
CMI Bucardo et al. Rotavirus diarrhoea in the hospital setting 603.e3Full genome sequencing of two G12 strains
Sequencing was extended to the remaining nine genes of the RV
genome from two G12 strains detected in 2012 and 2013.
Partial genes encoding VP6 (1000 bp), NSP1 (740 bp), NSP2
(935 bp), NSP3 (852 bp), NSP4 (649 bp) and NSP5 (552 bp),
together with partial genes encoding VP1 (564 bp), VP2 (665 bp)
and VP3 (676 bp), were sequenced using the methods and
primers described elsewhere [26,27]. GenBank accession
numbers for genes of the strains 203VN12 and 86VN13 are
KM668737 to KM668754 (Supplementary Table 1).
Phylogenetic analysis
Sequence alignment was performed by using the ClustalW al-
gorithm, version 1.83. Phylogenetic analysis and pairwise
nucleotide identities were performed by the Mega 6.0 software
package, and the phylogenetic trees were constructed as pre-
viously described [23].ResultsSharp increase of RV detection in hospital settings
A total of 185 (22%) of 837 children with diarrhoea were RV-
positive. Median age of RV-positive children was 12 months
(range 1 month to 10 years), with 66% in the group of 6 to 24
months of age, with boys more commonly found in the RV-
infected group than girls (61% vs. 39%). Peaks of RV detec-
tion occurred in May 2012 and April 2013 (Fig. 1A). The RV
detection rate increased signiﬁcantly in 2012, with 114 (29%) of
385 being RV positive compared to only 8 (6%) of 124 in 2011
(Table 1). Following this unusual RV increase, prevalence of RV
was slightly lower (19%) in 2013. RV detection rates variedFIG. 1. (A) Temporal distribution of rotavirus (RV) strains circulating amon
genotype was predominant, and peaks occurred during the late dry season. N
among different age groups during 2011 to 2013 in Nicaragua. G12 genotyp
months of age. Non-G12 refers to G4, G3, G1 and G2.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inbetween hospitals; for instance, in some of the hospital settings
the RV prevalence was >37% in 2012 (Table 1).
RV G12 emergence and predominance in 2012 and
2013
A subset of 156 (84%) of 185 RV-positive samples with sufﬁ-
cient material was analyzed by G genotyping (Table 2). The
predominant genotype was G12, accounting for 104 (69%) of
the RV-positive samples tested, followed by G4 (7%), G3 (6%),
G1 (4%) and G2 (0.6%), in addition to mixed infections of
G4:G3 (n = 4) and G4:G2 (n = 3) (Table 2). In 10% of these
samples, a genotype could not be assigned. Although G12 was
not detected at all in 2011, it accounted for 65% and 81% of the
RV-positive samples collected in 2012 and 2013, respectively
(Table 2). Notably, G12 was found in children of all ages
(Fig. 1B).
Nationwide spreading of G12P[8] of LIII in Nicaragua
Nucleotide sequencing showed that 11 (73%) of the selected
RV positive samples (n = 15), representing different hospitals of
Nicaragua and different years, carried VP7 genes with 99%
nucleotide homology to G12 strains recently detected in
several countries, including India, Kenya, Argentina and the
United States (Supplementary Fig. 1). Moreover, all Nicaraguan
G12 strains belonged to the globally emerging LIII lineage. The
remaining four sequenced strains had VP7 genes with G3 (n = 3)
and G1 (n = 1) speciﬁcities and nucleotide sequences with
99% homology to Nicaraguan G3 and Cuban G1 strains
(Supplementary Fig. 1). All successfully sequenced VP4 genes
(n = 14) carried P[8] speciﬁcity and clustered into LIII
(Supplementary Fig. 2). All P[8] of G12 strains subclustered
with P[8] derived from Kenyan, US and Argentinean strains, butg children in a hospital setting in Nicaragua from 2011 to 2013. G12
on-G12 refers to G4, G3, G1 and G2. (B) Frequency of RV detection
e infected all age groups with increased frequency in children 7 to 24
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e1–603.e7
TABLE 1. Rotavirus (RV) detection rates in the hospital setting among children £10 years of age from Nicaragua in 2011–2013
City Hospital name
2011 2012 2013 2011–2013
All cases RV, n (%) All cases RV, n (%) All cases RV, n (%) All cases RV, n (%)
Managua Fernando Velez Paiz 36 5 (13) 71 29 (40) 31 11 (35) 138 45 (32)
Manuel de Jesus Rivera 0 0 169 34 (20) 151 34 (22) 320 68 (21)
Masaya Humberto Alvarado Vasquez 15 2 (13) 24 9 (37) 36 4 (11) 75 15 (20)
Carazo Santiago Jinotepe 54 1 (1) 74 31 (41) 75 11 (14) 203 43 (21)
Matagalpa Cesar Amador Molina 19 0 (0) 47 11 (23) 35 3 (8) 101 14 (13)
All 124 8 (6) 385 114 (29) 328 63 (19) 837 185 (22)
603.e4 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMInot with P[8] from strains previously circulating in Nicaragua. In
contrast, the P[8] of G3 strains reported in this study sub-
clustered with P[8] circulating previously in Nicaraguan. The P
[8] gene from G1 clustered with P[8] from G12 RVs and was
identical to the VP4 gene of the Ro4426 strain from the United
States (Supplementary Fig. 2).
The Nicaraguan G12 RV genome was similar to the globally
emerging G12 strain. Both G12 RV strains selected for genome
sequencing analysis and circulating in 2012 (203VN12) and 2013
(86VN13) displayed a Wa-like genome: G12-P[8]-I1-R1-C1-
M1-A1-N1-T1-E1-H1. Nucleotide identities ranged from
99.9% to 99.2% between all 11 genes of strains 203VN12 and
86VN13 (Supplementary Table 1). Most genes of the 203VN12
strain were more similar to homologous genes of the strain
from Kenya than to the Argentinian strain and several other
global circulating G12 strains. Of interest, the NSP4 gene from
strains 203VN12 and 86VN13 were rather different (3% to
5.4%) compared to the NSP4 gene of other global G12 strains
(Supplementary Table 1).
G12-infected children with fecal IgA anti-RV
To investigate whether G12 RV infections correlated with the
absence of fecal IgA anti-RV, IgA was measured in a subset of
137 acute stool samples from RV-positive children (Table 3).
The results showed that 106 (77%) of 137 RV-positive children
had fecal IgA anti-RV titres of 1:160. Most RV-negative chil-
dren (79%, n = 52, Table 3) also had IgA anti-RV titres of
1:160. Very low titres (1:20) were observed in only 4 (3%)
TABLE 2. Predominance and persistence of G12 during two
consecutive years in Nicaragua. 2012–2013
Genotypea
All years,
n (%)
2011,
n (%)
2012,
n (%)
2013,
n (%)
G12 107 (69) 0 (0) 59 (65) 48 (81)
G4 11 (7) 2 (33) 8 (9) 1 (2)
G3 9 (6) 1 (17) 8 (9) 0 (0)
G1 6 (4) 0 (0) 5 (5) 1 (2)
G2 1 (0.6) 0 0 1 (2)
Mixb 7 (4) 3 (50) 3 (3) 1 (2)
NTc 15 (10) 0 (0) 8 (9) 7 (12)
Total 156 (100) 6 (100) 91 (100) 59 (100)
aStool sample was not sufﬁcient in 29 rotavirus-positive samples for genotyping.
bCoinfection with more than one genotype, of which four were cases of G4:G3
infection and three of G4:G2 infection.
cNT indicates not typeable with primers and methods used.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectRV-positive and 2 (4%) RV-negative subjects (Table 3). After
stratifying by genotype, it was observed that 75% of the G12
infections had IgA anti-RV titres of 1:160.DiscussionThe emergence and predominance of G12 RV inNicaragua during
2012 and 2013 is a distinctive event. The G12 genotype has not
previously been detected in this country—neither during the
prevaccine or postvaccine periods [4,23,28]. This emergence was
further associated with a more than twofold increase in hospital-
izations due to diarrhoea among children 5 years of age (2011,
n = 1418; 2012, n = 3300; 2013, n = 3439) (http://www.paho.org/
hq/index.php?option=com_content&view=article&id=1892:rota
virus-surveillance&Itemid=1623&lang=en). Taken together, these
results show that emergence of G12 can have a major and per-
sisting impact on hospitalization rates overmore than two seasons
in RV5-vaccinated populations. The capacity of G12 RV to infect
and persist in populations vaccinated with the monovalent RV
vaccine (RV1) remains to be elucidated.
Available data demonstrate that temporal and regional ﬂuc-
tuations of globally common RV genotypes occurred before the
introduction of RV5 vaccine into Nicaragua [23,29,30]. Studies
performed after vaccine introduction suggested that RV5
vaccination has not yet altered the historical pattern of RV
genotype ﬂuctuation [6,28]. Therefore, it is also possible that
after two seasons of G12 predominance, another genotype will
emerge and replace it. Nevertheless, it is possible that G12 will
become a common genotype in Nicaragua and the region, as
has occurred with other globally dominant genotypes (i.e. G1,
G2, G3 G4 and G9).
The ﬁnding that G12 strains in this study could to a high degree
symptomatically infect a population with a reported RV5 im-
munization rate of over 90% must be interpreted with caution
and in terms of vaccine uptake or vaccine-related immune
pressure [4]. The RV5 vaccine is based on the concept of
serotype-speciﬁc immunity (G1 to G4) [31]. Thus, one major
concern is whether the RV5 vaccine used in Nicaragua can
protect against new emerging genotypes, such as G12. Most of
the countries reporting increasing detection rates of G12 strainsious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e1–603.e7
TABLE 3. Fecal anti-RV5 IgA titres among Nicaraguan children with acute RV diarrhoea mainly associated with G12 genotypes,
2011–2013, and children with non-RV diarrhoea
Acute anti-RV5 IgA titrea
Diarrhoea, n (%) G-type infection, n (%)
Non-RV RV G12 G4 G3 G1 G2 Mix
1:160 41 (79) 106 (77) 77 (75) 9 (82) 9 (100) 4 (66) 1 (100) 6 (86)
1:80 7 (13) 23 (17) 19 (18) 1 (9) 0 2 (33) 0 1 (14)
1:40 2 (4) 4 (3) 3 (3) 1 (9) 0 0 0 0
1:20 2 (4) 4 (3) 4 (3) 0 0 0 0 0
All tested 52 (100) 137 (100) 103 (100) 11 (100) 9 (100) 6 (100) 1 (100) 7 (100)
OD, optical density; PBS, phosphate-buffered saline; RV, rotavirus.
aReciprocal of the highest stool dilution with OD 0.100 was considered sample titre. For negative control, media and standard deviation of the OD for all dilutions intra- and
interassay were 0.06 and 0.017. Media of the OD of PBS readings was 0.037 (range 0.035–0.039, SD = 0.009).
CMI Bucardo et al. Rotavirus diarrhoea in the hospital setting 603.e5do not have RV vaccination in their national immunization
schedule, and vaccine-related selective pressure is therefore
unlikely [8–11]. It is more likely that G12 emergency and
persistence in Nicaragua was due the presence of a susceptible
population immunological naive to this globally emerging strain.
Because of logistic constraints, vaccination status was only
documented for 26 of the RV-positive children in this study, 20 of
whom had received all recommended vaccine doses. The RV
genotypes observed in these children were G12 (n = 10), G4
(n = 2), G2 (n = 1), G1 (n = 1), mixed infections (n = 1) and
nontypeable strains (n = 5).
The speciﬁc immune component of protection induced by the
RV5 vaccine is still unclear, and a good marker of protection re-
mains to be established [32]. In natural RV infections, Matson et al.
[33] found that higher fecal IgA titres were associated with pro-
tection against infection and illness. In contrast, an adult challenge
study found that fecal anti-RV IgA titres could not be correlated to
either infection or illness [34]. Although a clear correlation of
protection has not been established, some studies have suggested
serumand fecal anti-RV IgA to be infectionmarkers,with antibody
levels peaking at days 14 to 17 after inoculation [22,32,35]. A
challenge study using the quadrivalent precursor of the RV5
vaccine found that no placebo recipient had a threefold or more
increase in fecal anti-RV IgA, whereas 83% of vaccine recipients
had an increase after one dose [36]. Anti-RV IgA titres were also
found to be a poor correlate of protection in other studies [37]. In
the current study, 75% of the G12-positive children had a fecal
anti-RV IgA titre of 160, which was similar as RV-negative
children (79%), indicating that most children infected with G12
viruses had previously been in contact with either RV of vaccine
origin or wild-type strains; thus, these fecal IgA antibody titres
were not protective. Indeed, vaccination failure was documented
in 10 children (age range 6 to 24 months, median 12 months)
symptomatically infected with G12.
The G12 virus found in Nicaragua displayed a Wa-like
genome (G12-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1), which is
markedly different to the vaccine genome (G1/2/3/4/6-P[8]/P
[5]-I2-R2-C2-M1/M2-A3-N2-T6-E2-H3), with the exception of
VP4. Additionally, nucleotide identity data suggest that the NSP4Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Ingene in the Nicaraguan G12P[8] RV strains may have been
acquired by a reassortment event (Supplementary Table 1).
However, RV5 vaccine has been shown to exert similar effec-
tiveness against homotypic and heterotypic RV strains [38]. For
instance, in Nicaragua, RV5 vaccination has exhibited large
protection to many other Wa-like strains, such as G1P[8], G3P
[8], G4P[8] and G2P[4], the detection rates of which have
considerably decreased in the last few years, as observed in the
current study and in other studies [4,5,28]. Nevertheless, the
emergence and high prevalence of G12 RV in a vaccinated
population with RV5 (G1/2/3/4:P[8]) vaccine suggest that G-
type-speciﬁc immune protection may be required to prevent
disease and that new strains with VP7 genotypes not included in
the vaccine may lead to extensive vaccine failures. However,
there may be several additional factors contributing to RV
vaccine protection, including immune and nutritional compo-
nents, as well as host histo–blood group antigens that mediate
susceptibility to RV infection [39]. More studies are needed to
clarify the risk factors behind RV vaccine failures.Transparency declarationAll authors report no conﬂicts of interest relevant to this
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